Skip navigation
Watchlist Sponsored By :

Current DateTime: 01:50:51 24 Jul 2008
LinksList Documentid: 24355697

Current DateTime: 01:50:51 24 Jul 2008
LinksList Documentid: 24890560
  • Texas is Tops in 2008

      Texas knocked out last year's top state for business, Virginia. How did your state fare in our annual study?

  • Powering the Planet

      Energy has become the most common denominator in the global economy. Ultimately, it may be the great unifier. After all, imagine a world without energy, affordable energy.

  • Apple & The New iPhone

      Second acts should not be taken for granted. Apple and Steve Jobs have yet to make that mistake and they're unlikely to do so with the launch of the new iPhone.

Genentech Faces ImClone Pressure on Cancer Drug
By Reuters | 21 Apr 2008 | 05:15 AM ET
Font size:

Genentech's blockbuster cancer drug Avastin faces a big challenge from ImClone Systems's [IMCL  Loading...      ()   ] Erbitux in lung cancer, Morgan Stanley analysts said on Monday, citing unpublished data.
Genetech
Marcio Jose Sanchez / AP
The Genentech campus is seen in South San Francisco, California.

The brokerage said it had learnt from "a reliable public source" that ImClone's [DNA  Loading...      ()   ] medicine had demonstrated an unexpected survival benefit in a second Phase III trial -- the so-called BMS-099 trial for first line metastatic lung cancer.

The revelation came as Genentech announced fresh findings from a clinical trial called Avail showing that Avastin improved progression-free survival in patients with non-small cell lung cancer (NSCLC) but did not prolong their overall survival.

The results mean Erbitux has two Phase III trials with proven survival benefit compared with only one for Avastin, increasing the chances that Erbitux could pose a serious threat to Avastin in the lung cancer treatment market in future.

Avastin, which is vital to the future prospects of both Genentech and its associate Roche Holding, is already approved in NSCLC in the United States and Europe.

Erbitux was initially developed for colon cancer but its sponsors now want to use it in a wider range of tumour types.

It is sold in Europe by Germany's Merck KGaA and in the United States by Bristol-Myers Squibb [BMY  Loading...      ()   ].

Morgan Stanley said the companies had declined to confirm the Erbitux clinical trial news, but shares in Germany's Merck KGaA were likely to rally strongly, ahead of the big ASCO cancer meeting at the end of May.

"An additional 400 million euros revenue for Erbitux in 2012 would translate into a 15 percent increase in our Merck KGaA EPS estimate," the brokerage said.

"We are maintaining our current forecast of 300 million euros in lung in 2012 unchanged until we see the FLEX and BMS-099 data."

Copyright 2008 Reuters. Click for restrictions.

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis